Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 4/2011

01-04-2011 | Research Articles

Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study)

Authors: Agustí Barnadas, Ricard Mesía, Margarita Majem, Ramón Galiana, Antonio López-Pousa, José M. de Vega, Mireia Margelí, Vicente Valentí, Lluís Anglada, Ariadna Lloansí, Antonio Arellano

Published in: Clinical and Translational Oncology | Issue 4/2011

Login to get access
Metadata
Title
Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study)
Authors
Agustí Barnadas
Ricard Mesía
Margarita Majem
Ramón Galiana
Antonio López-Pousa
José M. de Vega
Mireia Margelí
Vicente Valentí
Lluís Anglada
Ariadna Lloansí
Antonio Arellano
Publication date
01-04-2011
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 4/2011
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-011-0650-9

Other articles of this Issue 4/2011

Clinical and Translational Oncology 4/2011 Go to the issue

Educational Series/Red Series

Recent advances in oncolytic virus design

Special Article

Oncology outside hospital: a new experience for the benefit of longer survivors

News and Views/The Journalist Corner

ECO Foundation

Research Articles

Interleukin-15 enhances T-cell responses by stimulation with dendritic cells

Educational Series/Purple Series

Glioblastoma: changing expectations?

Editorial

Pseudomyxoma peritonei: a rare disease and a disease model in peritoneal surface oncology
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits